Organogenesis Holdings (ORGO)

• Market cap: $578M
• 1 day: 0.66%
• 5 days: 9.35%
• 1 month: -12.64%
• 3 months: 21.93%
• 6 months: 62.86%
• Year to date: 50.50%
• 1 year: 99.13%
• 5 years: 20.95%
• 10 years: -53.23%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Employees: 869

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

469% more call options, than puts

Call options by funds: $74K | Put options by funds: $13K

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

17% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 35

10% more capital invested

Capital invested by funds: $182M [Q3] → $200M (+$18.5M) [Q4]

7% more funds holding

Funds holding: 111 [Q3] → 119 (+8) [Q4]

1.83% more ownership

Funds ownership: 47.9% [Q3] → 49.74% (+1.83%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $6 32% upside
• Avg. target: $6 32% upside
• High target: $6 32% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Morgan Stanley Drew Ranieri 25% 1-year accuracy 2 / 8 met price target

32% upside $6

Equal-Weight Maintained

5 Mar 2025